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Hormone replacement therapy (HRT) use has been found to be
inversely associated with colorectal cancer in several case–control
and cohort studies (Franceschi and La Vecchia, 1998). A meta-
analysis of 20 studies published up to 1997 on colon cancer in
women led to a summary relative risk (RR) of 0.85 (95%
confidence interval (CI) 0.73–0.99) (Hebert-Croteau, 1998). The
suggested protective effect of HRT was stronger in studies
published since 1990 and among current or recent users (RR 0.69;
95% CI 0.52–0.91).
The adverse effect of HRT use in respect to cancer of the breast,
endometrium (IARC, 1999) and, possibly, ovary (Negri et al,
1999) is consistent with the well established direct association
between age at menopause and risk at these sites. For breast
cancer, the increase in risk for each year of HRT use is similar to
the effect of 1-year delay in menopause (Collaborative Group on
Hormonal Factors in Breast Cancer, 1997). For colorectal cancer,
no consistent relationship has been shown with age at menopause
(La Vecchia and Franceshi, 1991; Jacobs et al, 1994; Kampman et
al, 1994, 1997; Martinez et al, 1997; Troisi et al, 1997), but the
issue has not been considered in depth. In order to further clarify
the influence of menopause on colorectal cancer, we have re-eval-
uated data collected in Italy between 1985 and 1996.
SUBJECTS AND METHODS
The data were derived from two case–control studies on colorectal
cancer: the first conducted between 1985 and 1991 in the greater
Milan area (Negri et al, 1989) and the province of Pordenone, in
Northeast Italy (Franceschi et al, 1991); and the second conducted
between 1992 and 1996 in the provinces of Pordenone and Gorizia
in Northeast Italy; the urban areas of Milan and Genoa and the
province of Forlì in northern Italy; Latina in central Italy; and the
urban area of Naples in southern Italy (Talamini et al, 1998).
Centrally trained interviewers identified and questioned cases of
colorectal cancer and controls during their hospital stay.
Cases included 1536 women below age 75 years with histologi-
cally confirmed cancer (i.e. diagnosed within the year before inter-
view) of the colon (994 cases, median age 61) and rectum (542
cases, median age 62), admitted to the major teaching and general
hospitals in the areas under surveillance.
The control group included 3110 women younger than 75 years
(median age of 57), residing in the same geographical areas and
admitted for a wide spectrum of acute, non-neoplastic, non-diges-
tive tract, non-hormone-related disorders to the same network of
hospitals from which cases were recruited. Of these, 43% were
admitted for traumas, 14% had non-traumatic orthopaedic dis-
orders, 13% had acute surgical conditions, 6% had eye conditions
and 24% had other miscellaneous diseases, such as ear, nose and
throat, skin, or dental disorders. Cases and controls had the same
referral pattern. Fewer than 5% of cancer cases and control
subjects refused to be interviewed.
Structured questionnaires were used to collect information on
sociodemographic factors, personal characteristics and habits
(such as smoking, alcohol and coffee consumption), frequency of
consumption of selected foods and a problem-oriented medical
history. Information was also collected on menstrual and reproduc-
tive factors and on the use of oral contraceptives and HRT
(Fernandez et al, 1998). Women were considered post-menopausal
if they reported no menstrual periods in the 12 months prior to
colorectal cancer diagnosis or hospital admission (controls), or
had undergone hysterectomy and/or bilateral oophorectomy.
To examine the effect of menopause on colorectal cancer risk
independently of the effect of HRT, most analyses were restricted
to women who had never used HRT. Odds ratios (ORs), together
with the corresponding 95% CIs, were derived from unconditional
multiple logistic regression equations, fitted by the method of
maximum likelihood (Breslow and Day, 1980). Terms included in
the regression equations were age (in quinquennia plus a contin-
uous term), centre, study period, education, parity, vegetable
intake and body mass index (BMI, kg m–2). Allowance for other
potentially confounding variables (smoking habit, alcohol
drinking, coffee intake, meal frequency, family history of
colorectal cancer and, for the more recent study, physical activity,
total energy intake and aspirin use) did not substantially modify
any of the ORs in Tables 1 and 2.
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RESULTS
Table 1 shows the distribution of cases of cancer of the colon and
rectum and control subjects according to menopause-related vari-
ables. Compared to premenopausal, post-menopausal women who
had never used HRT were at 1.5-fold increased risk (95% CI
1.1–2.0) of colon cancer. Conversely, women who had ever taken
HRT had an OR of 0.9 (95% CI 0.6–1.4). Type of menopause did
not seem to modify colon cancer risk. Women who reported
menopause at age 50–52 years had an OR of 1.5 (95% CI 1.1–1.9)
compared to those whose menopause was at age 44 or less, but the
trend in risk was not linear. Women whose menopause occurred
1–9 years before diagnosis had a substantially higher risk (OR =
1.7, 95% CI 1.2–2.3) than premenopausal ones. Thereafter, ORs
declined progressively with time since menopause. Trend by years
since menopause among post-menopausal women was significant
(Table 1). For rectal cancer, no significant associations with age at
menopause or years since menopause were found. Ever users of
HRT showed decreased risk of rectal cancer compared to
premenopausal women (Table 1).
The relation of colon cancer risk with time since menopause
differed significantly according to BMI tertile (Table 2). The risk
elevation in the 10 years subsequent to menopause seemed restricted
to women with BMI below 23 (OR = 2.2; 95% CI 1.3–3.7) (c2
1 for
trend = 6.00, P= 0.02). Conversely, the decline in risk by years since
menopause was not significant in women whose BMI was between
23 and 26 (c2
1 for trend = 1.37, P = 0.24) and was absent among
those with BMI higher than 26 (c2
1 for trend = 0.16, P = 0.69).
Trends by age at and years since menopause did not differ between
women with natural and those with surgical menopause.
Table 1 Odds ratios (ORs) and corresponding 95% confidence intervals (CIs)a of cancer of the colon and rectum
according to menopausal status, type of and age at menopause, and years since menopause. Italy, 1985–1996
Colon cancer Rectal cancer Controls
No. OR (95% CI) No. OR (95% CI) No.
Menopausal statusc,d
Pre- 170 1b 88 1b 897
Post 770 1.46 (1.05–2.04) 429 1.19 (0.76–1.86) 1973
HRT-users 54 0.93 (0.60–1.43) 23 0.56 (0.31–1.03) 235
Type of menopausec,d
Natural 619 1b 343 1b 1578
Surgical 149 1.10 (0.88–1.38) 85 1.19 (0.91–1.57) 390
Age at menopause (years)c,d
<45 124 1b 84 1b 390
45–49 199 1.21 (0.92–1.58) 113 0.96 (0.69–1.32) 534
50–52 288 1.46 (1.12–1.89) 152 1.05 (0.77–1.42) 630
³53 157 1.17 (0.87–1.57) 78 0.76 (0.53–1.08) 412
c1
2(trend) 2.20; P=0.14 1.33; P=0.25
Years since menopausec,d
Pre-menopausal 170 1b 88 1b 897
<10 254 1.66 (1.21–2.28) 120 1.20 (0.79–1.82) 698
10–19 309 1.18 (0.80–1.73) 191 1.26 (0.78–2.06) 851
³20 205 1.09 (0.69–1.72) 116 1.14 (0.64–2.01) 417
c1
2(trend)e 5.07; P=0.02 0.06; P=0.80
aEstimates from unconditional multiple regression equations including terms for age, study centre, educational years,
parity, vegetable intake and body mass index. b Reference category. c Ever users of hormone replacement therapy
(HRT) are not included. d Sums do not add up to the total because of a few missing values. e Premenopausal women
are excluded from trend analyses.
Table 2 Odds ratios (ORs) and corresponding 95% confidence intervals (CIs)a,b,c of colon cancer by years since menopause and body mass index (BMI); Italy,
1985–96
Body mass index (BMI)
Years since <23 23–26 >26
menopauseb Cases:Controlsc OR Cases:Controls OR Cases:Controls OR
(95% CI) (95% CI) (95% CI)
Premenopausal 85:392 1d 45:250 1d 40:255 1d
<10 95:184 2.21 (1.33–3.69) 82:230 1.37 (0.77–2.45) 77:281 1.34 (0.75–2.40)
10–19 104:244 1.27 (0.67–2.40) 89:264 0.77 (0.37–1.61) 116:341 1.34 (0.69–2.61)
³20 71:137 0.97 (0.45–2.08) 66:122 0.85 (0.36–1.99) 68:157 1.24 (0.57–2.70)
c1
2(trend)e 6.00; P=0.02 1.37; P=0.25 0.16; P=0.69
aEstimates from unconditional multiple regression equations including terms for age, study centre, educational years, parity and vegetable intake. bEver users of
hormone replacement therapy are not included. cSums do not add up to the total because of missing values. dReference category. 
ePremenopausal women are excluded from trend analyses.1862 S Franceschi et al
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DISCUSSION
The main finding is that post-menopausal women have a higher
risk of colon, but not rectal, cancer than do premenopausal women.
An adverse effect of late menopause is consistent with the findings
of some previous studies (Kampman et al, 1994; Martinez et al,
1997). In addition, colon cancer incidence data in developed coun-
tries show an excess in males, compared to females, from approxi-
mately age 50 years (Parkin et al, 1997). Relatively greater colon
cancer incidence in younger women than men suggests that
oestrogen exposure may be predisposing. However, in the form of
HRT, oestrogens seem to be protective (Franceschi and La
Vecchia, 1998). In fact, HRT users in our study were not at
increased risk of colon cancer compared to premenopausal
women. Furthermore, the risk increase after menopause seems
transient and restricted to lean women, i.e. those who experience
lowest levels of circulating oestrogens and sex-hormone binding
globulins when ovarian function ceases (Burger et al, 1995).
Risk increase in the years subsequent to menopause, however,
may be due to endocrinological changes other than the fall in
oestrogens, such as high levels of follicle-stimulating hormone,
lutenizing hormone, or other pituitary tropic hormones (e.g.
growth-hormone) in the peri- and early post-menopausal period
(Burger et al, 1995). Additional complexity is added by the
discovery of a second class of oestrogen receptors (ER) (i.e. 
ER-b) which has a different tissue distribution from the classical
ER-a, as well as a different response after binding ligand (Kuiper
and Gustafson, 1997). Finally, colonic mucosa can regulate
oestrogen action by locally expressed metabolizing enzymes
(English et al, 1999). Interconversion of oestradiol (E2) to less
potent oestrone (E1) was lower in colonic tumours compared to
normal mucosa (English et al, 1999). E1, but not E2, was shown to
significantly decrease proliferation when added to colonic epithe-
lial cell lines (Di Domenico et al, 1996; English et al, 1999).
Gradually after menopause, the ratio between E1 and E2 increases,
reflecting the declining follicular steroidogenesis and the
increasing importance of peripheral aromatization of androgens to
E1 (Rannevik et al, 1995). E1, but not E2, is contained in one of the
most commonly prescribed HRT (i.e. conjugated oestrogens)
(English et al, 1999).
ORs by age at and recency of menopause were unmodified by
stratification and adjustment for single year of age. This ensures
that age did not account for our findings. Infrequent HRT use in
Italy allowed the study of menopause in a large number of women
who had never used such therapy. Misclassification of self-
reported age at natural menopause does not seem systematic
(Hahnn et al, 1997), and our findings among women who under-
went natural menopause were replicated among those who under-
went surgical menopause. However, the potential influence of
menopause on colon cancer should be reconsidered in larger
studies or pooled analyses to evaluate risk modification by single
year since menopause.
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